Data from phase-I clinical trial have demonstrated that three glioblastoma patients were subjected to collection of peripheral mononuclear cells that were further engineered to CD8+ cytotoxic T lymphocytes expressing IL13-zetakine. The gene discussed is IL13; the disease is glioblastoma.